Comparative efficacy and safety of baricitinib plus sulfasalazine versus tnf-α inhibitors and sulfasalazine monotherapy in reactive arthritis: a 12-MONTH randomized study

Mullokulov J.J., Akhmedov Kh.S.

Вестник Ассоциации пульмонологов Центральной Азии · 2025-yil

Annotatsiya

Reactive arthritis (ReA) is a post-infectious spondyloarthritis characterized by arthritis, enthesitis, and extra-articular features. Conventional treatments such as sulfasalazine (SSZ) show modest benefit, while TNF-α inhibitors are effective but limited by cost and accessibility. Baricitinib, a JAK1/2 inhibitor, offers a novel oral therapeutic strategy, though evidence in ReA is scarce.

Maqola ma’lumotlari
MualliflarMullokulov J.J., Akhmedov Kh.S.
JurnalВестник Ассоциации пульмонологов Центральной Азии
NashriyotАссоциация Пульмонологов Центральной Азии
ISSN2181-4988
Nashr sanasi2025-10-18
Jild13
Son8
Betlar21-26
TilIngliz
Ilmiy sohaTibbiyot
Indeksga qo‘shilgan2026-08-27

Maqolaning asl sahifasi

Kalit so‘zlar

reactive arthritis, baricitinib, adalimumab, DAREA, BASDAI.

Ilmiy soha

Tibbiyot

Iqtibos keltirish

APAMullokulov J.J., Akhmedov Kh.S. (2025). COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB PLUS SULFASALAZINE VERSUS TNF-Α INHIBITORS AND SULFASALAZINE MONOTHERAPY IN REACTIVE ARTHRITIS: A 12-MONTH RANDOMIZED STUDY. Вестник Ассоциации пульмонологов Центральной Азии, 13(8), 21-26. https://journals.tnmu.uz/index.php/bapca/article/view/2469
GOST (OAK)Mullokulov J.J., Akhmedov Kh.S. COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB PLUS SULFASALAZINE VERSUS TNF-Α INHIBITORS AND SULFASALAZINE MONOTHERAPY IN REACTIVE ARTHRITIS: A 12-MONTH RANDOMIZED STUDY // Вестник Ассоциации пульмонологов Центральной Азии. – 2025. – T. 13, № 8. – P. 21-26.
MLAMullokulov J.J., Akhmedov Kh.S. “COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB PLUS SULFASALAZINE VERSUS TNF-Α INHIBITORS AND SULFASALAZINE MONOTHERAPY IN REACTIVE ARTHRITIS: A 12-MONTH RANDOMIZED STUDY.” Вестник Ассоциации пульмонологов Центральной Азии, 13(8), 21-26, 2025. https://journals.tnmu.uz/index.php/bapca/article/view/2469
ChicagoMullokulov J.J., Akhmedov Kh.S. “COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB PLUS SULFASALAZINE VERSUS TNF-Α INHIBITORS AND SULFASALAZINE MONOTHERAPY IN REACTIVE ARTHRITIS: A 12-MONTH RANDOMIZED STUDY.” Вестник Ассоциации пульмонологов Центральной Азии, 13(8), 21-26 (2025). https://journals.tnmu.uz/index.php/bapca/article/view/2469
HarvardMullokulov J.J., Akhmedov Kh.S (2025) ‘COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB PLUS SULFASALAZINE VERSUS TNF-Α INHIBITORS AND SULFASALAZINE MONOTHERAPY IN REACTIVE ARTHRITIS: A 12-MONTH RANDOMIZED STUDY’, Вестник Ассоциации пульмонологов Центральной Азии, 13(8), 21-26. https://journals.tnmu.uz/index.php/bapca/article/view/2469
BibTeX
@article{mullokulovjjakhmedovkhs2025,
  title = {COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB PLUS SULFASALAZINE VERSUS TNF-Α INHIBITORS AND SULFASALAZINE MONOTHERAPY IN REACTIVE ARTHRITIS: A 12-MONTH RANDOMIZED STUDY},
  author = {Mullokulov J.J., Akhmedov Kh.S.},
  journal = {Вестник Ассоциации пульмонологов Центральной Азии},
  year = {2025},
  volume = {13},
  number = {8},
  pages = {21-26},
  url = {https://journals.tnmu.uz/index.php/bapca/article/view/2469}
}

Boshqa maqola uchun iqtibos tayyorlash

Вестник Ассоциации пульмонологов Центральной Азии jurnalidan boshqa maqolalar

Вестник Ассоциации пульмонологов Центральной Азии — barcha maqolalar · 2025-yil arxivi

Tibbiyot sohasidagi boshqa maqolalar

Tibbiyot sohasidagi OAK jurnallari